Thermo Fisher Scientific Inc. (NYSE:TMO) has been given an average rating of “Buy” by the seventeen analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $298.23.

TMO has been the topic of a number of analyst reports. Needham & Company LLC cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating and set a $315.00 price target on the stock. in a research note on Tuesday. They noted that the move was a valuation call. Argus upped their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. UBS Group cut shares of AGL Energy to a “sell” rating in a research note on Thursday, May 23rd. Finally, BTIG Research upped their price target on shares of Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd.

In other news, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $268.29, for a total value of $670,725.00. Following the transaction, the chief financial officer now owns 40,029 shares in the company, valued at approximately $10,739,380.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 50,713 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the completion of the transaction, the chief executive officer now owns 302,193 shares in the company, valued at approximately $82,562,149.53. The disclosure for this sale can be found here. Insiders have sold a total of 53,488 shares of company stock worth $14,600,474 in the last 90 days. Company insiders own 0.45% of the company’s stock.

Large investors have recently modified their holdings of the company. Boston Family Office LLC lifted its stake in shares of Thermo Fisher Scientific by 12.4% in the fourth quarter. Boston Family Office LLC now owns 31,589 shares of the medical research company’s stock valued at $7,069,000 after buying an additional 3,495 shares in the last quarter. Chilton Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 5.0% during the fourth quarter. Chilton Capital Management LLC now owns 60,642 shares of the medical research company’s stock valued at $13,571,000 after purchasing an additional 2,891 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its position in shares of Thermo Fisher Scientific by 5.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 77,446 shares of the medical research company’s stock valued at $17,332,000 after purchasing an additional 4,196 shares in the last quarter. Pitcairn Co. lifted its position in shares of Thermo Fisher Scientific by 5.1% during the fourth quarter. Pitcairn Co. now owns 18,515 shares of the medical research company’s stock valued at $4,144,000 after purchasing an additional 893 shares in the last quarter. Finally, JOYN Advisors Inc. lifted its position in shares of Thermo Fisher Scientific by 37.1% during the fourth quarter. JOYN Advisors Inc. now owns 584 shares of the medical research company’s stock valued at $131,000 after purchasing an additional 158 shares in the last quarter. Hedge funds and other institutional investors own 87.98% of the company’s stock.

Shares of NYSE:TMO traded down $3.91 during midday trading on Friday, reaching $289.82. The company’s stock had a trading volume of 1,593,135 shares, compared to its average volume of 1,391,755. The business has a 50 day moving average of $288.56. The stock has a market capitalization of $117.49 billion, a price-to-earnings ratio of 26.06, a P/E/G ratio of 1.93 and a beta of 1.10. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. Thermo Fisher Scientific has a 12-month low of $208.34 and a 12-month high of $305.45.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.07. The firm had revenue of $6.13 billion for the quarter, compared to the consensus estimate of $6.04 billion. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.50 EPS. As a group, analysts predict that Thermo Fisher Scientific will post 12.2 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Municipal Bonds

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.